COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

OBJECTIVE: To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease. METHODS: We conducted a 12-month, prospective, non-randomised, open-label, comparative trial of adults with either rheumatoid arthritis (RA, n=131) on stable tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Colmegna, Ines, Valerio, Valeria, Amiable, Nathalie, Useche, Mariana, Rampakakis, Emmanouil, Flamand, Louis, Rollet-Labelle, Emmanuelle, Bessette, Louis, Fitzcharles, Mary-Ann, Hazel, Elizabeth, McCormack, Deirdre, Michou, Laëtitia, Panopalis, Pantelis, Langlois, Marc-André, Bernatsky, Sasha, Fortin, Paul R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689388/
https://www.ncbi.nlm.nih.gov/pubmed/38030231
http://dx.doi.org/10.1136/rmdopen-2023-003400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689388/
https://www.ncbi.nlm.nih.gov/pubmed/38030231
http://dx.doi.org/10.1136/rmdopen-2023-003400

Ejemplares similares